Skip to main content
NCBI home page
Atencion Primaria logoLink to Atencion Primaria
. 2013 Apr 5;28(7):478–483. [Article in Spanish] doi: 10.1016/S0212-6567(01)70425-8

Principales estudios de intervención (ensayos clínicos) en la diabetes tipo 2: implicaciones en atención primaria

JJ Mediavilla Bravo a, J Méndola b,*
PMCID: PMC7676000  PMID: 11718644

The content is available as a PDF (367.0 KB).

Contributor Information

J.J. Mediavilla Bravo, Email: jmediavillab@meditex.es.

J. Méndola, Email: josep.mendola@pharma.novartis.com.

Bibliografía

  • 1.King H., Aubert R.E., Herman W.H. Global burden of diabetes, 1995–2025. Diabetes Care. 1998;21:1414–1431. doi: 10.2337/diacare.21.9.1414. [DOI] [PubMed] [Google Scholar]
  • 2.McCarty D., Amos A., Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med. 1997;14(Supl 5):1–85. [PubMed] [Google Scholar]
  • 3.Fagot-Campagna A., Burrows N.R., Williamson D.F. The public health epidemiology of type 2 diabetes in children and adolescents: a case study of American Indian adolescents in the Southwestern United States. Clin Chim Acta. 1999;286:81–95. doi: 10.1016/s0009-8981(99)00095-9. [DOI] [PubMed] [Google Scholar]
  • 4.Dabelea D., Hanson R.L., Bennett P.H., Roumain J., Knowler W.C., Pettitt D.J. Increasing prevalence of type 2 diabetes in American Indian children. Diabetologia. 1998;41:904–910. doi: 10.1007/s001250051006. [DOI] [PubMed] [Google Scholar]
  • 5.Laakso M. Hyperglycaemia and cardiovascular disease in type 2 diabetes. Diabetes. 1999;48:937–942. doi: 10.2337/diabetes.48.5.937. [DOI] [PubMed] [Google Scholar]
  • 6.Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care. 1995;18:258–271. doi: 10.2337/diacare.18.2.258. [DOI] [PubMed] [Google Scholar]
  • 7.UK Prospective Diabetes Study Group Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet. 1998;352:837–853. [PubMed] [Google Scholar]
  • 8.Stratton I.M., Adler A.I., Neil A.W., Matthews D.R., Manley S.E., Cull C.A. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–412. doi: 10.1136/bmj.321.7258.405. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.The DCCT Research Group The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes. 1995;44:968–983. [PubMed] [Google Scholar]
  • 10.Okhubo Y., Kishikawa H., Araki E., Miyata T., Isami S., Motoyoshi S. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin dependent diabetes mellitus: a randomized prospective 6-year study. Diabet Res Clin Pract. 1995;28:103–117. doi: 10.1016/0168-8227(95)01064-k. [DOI] [PubMed] [Google Scholar]
  • 11.Shichiri M., Kishikawa H., Ohkubo Y., Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care. 2000;23(Supl 2):21–29. [PubMed] [Google Scholar]
  • 12.Hanefeld M., Fischer S., Julius U., Schulze J., Schwanebeck U., Schmechel H. The DIS Group. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia. 1996;39:1577–1583. doi: 10.1007/s001250050617. [DOI] [PubMed] [Google Scholar]
  • 13.UK Prospective Diabetes Study Group Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38) BMJ. 1998;317:703–713. [PMC free article] [PubMed] [Google Scholar]
  • 14.UK Prospective Diabetes Study Group (UKPDS) A randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes (UKPDS 28) Diabetes Care. 1998;21:87–92. doi: 10.2337/diacare.21.1.87. [DOI] [PubMed] [Google Scholar]
  • 15.Ramlo-Halsted B.A., Edelman S.V. The natural history of type 2 diabetes. Implications for clinical practice. Prim Care. 1999;26:771–789. doi: 10.1016/s0095-4543(05)70130-5. [DOI] [PubMed] [Google Scholar]
  • 16.Turner R.C., Cull C.A., Frighi V., Holman R.C. Glycemic control with diet, sulfonylurea, metformin or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UKPDS Study Group. JAMA. 1999;281:2005–2012. doi: 10.1001/jama.281.21.2005. [DOI] [PubMed] [Google Scholar]
  • 17.UK Prospective Diabetes Study Group (UKPDS) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet. 1998;352:854–865. [PubMed] [Google Scholar]
  • 18.Avignon A., Radauceanu A., Monnier L. Non-fasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care. 1997;20:1822–1826. doi: 10.2337/diacare.20.12.1822. [DOI] [PubMed] [Google Scholar]
  • 19.Polonsky K.S., Given B.D., Hirsch L.J., Tillil H., Shapiro E.T., Beebe C. Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med. 1988;318:1231–1239. doi: 10.1056/NEJM198805123181903. [DOI] [PubMed] [Google Scholar]
  • 20.Giugliano D., Ceriello A., Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care. 1996;19:257–267. doi: 10.2337/diacare.19.3.257. [DOI] [PubMed] [Google Scholar]
  • 21.The DECODE study group European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet. 1999;354:617–621. [PubMed] [Google Scholar]
  • 22.Muggeo M., Verlato G., Bonora E. Long-term instability of fasting plasma glucose predicts mortality in elderly NIDDM patients: the Verona Diabetes Study. Diabetologia. 1995;38:672–679. doi: 10.1007/BF00401838. [DOI] [PubMed] [Google Scholar]
  • 23.Holman R.R., Cull C.A., Turner R.C. A randomized double-blind trial of acarbosa in type 2 diabetes shows improved glycemic control over 3 years. Diabetes Care. 1999;22:960–964. doi: 10.2337/diacare.22.6.960. [DOI] [PubMed] [Google Scholar]
  • 24.Horton E., Clinkingbeard C., Gatlin M., Foley J., Mallows S., Shen S. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose spikes in type 2 diabetes. Diabetes Care. 2000;23:1660–1665. doi: 10.2337/diacare.23.11.1660. [DOI] [PubMed] [Google Scholar]
  • 25.Hanefeld M., Bouter K.P., Dickinson S., Guitard C. Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia. Diabetes Care. 2000;23:202–207. doi: 10.2337/diacare.23.2.202. [DOI] [PubMed] [Google Scholar]

Articles from Atencion Primaria are provided here courtesy of Elsevier

RESOURCES